Evidence map›Paper›PMID 41425941›Full record

ArticleFrontiers in microbiology2025

Generative AI in microbial evolution and resistance: toward robust, explainable, and equitable predictions.

Fahim Sufi

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Frontiers in bioinformatics · 2026
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Fahim SufiCOEUS Institute, New Market, VA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is one of the most urgent challenges in modern microbiology, both an evolutionary inevitability and a global health crisis shaped by clinical practices, ecological disruption, and social inequities. Generative artificial intelligence (AI) and large language models (LLMs) present new opportunities to anticipate resistance pathways, design novel antimicrobial agents, and guide interventions that are informed by evolutionary dynamics. Their successful integration, however, depends on addressing three fundamental imperatives. The first is evolutionary robustness, requiring models that incorporate mutation, horizontal gene transfer, and adaptive landscapes to move beyond retrospective classification toward predictive evolutionary inference. The second is explainability and biosafety, which demand interpretable and biologically credible outputs that clinicians, microbiologists, and policymakers can trust, while safeguarding against dual use risks. The third is data equity, which calls for strategies that mitigate structural biases in global microbial datasets and ensure that predictive systems serve the populations most affected by AMR. This Perspective advances the view that generative AI must be conceived as a transformative epistemic infrastructure that is evolution aware, transparent, and globally inclusive, capable of supporting sustainable drug discovery, adaptive surveillance, and equitable microbiological futures.

Indexed as

antimicrobial resistancedrug discoveryexplainability and biosafetyexplainable AIgenerative artificial intelligenceGPT in medical domainmicrobial evolution

Identifiers

PMID41425941
PMCPMC12714630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.